Ipoglicemia: trattamento e strategie di prevenzione
|
|
- Merry Lambert
- 6 years ago
- Views:
Transcription
1 Ipoglicemia: trattamento e strategie di prevenzione Antonio Ceriello Insititut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona Spain
2 Frequency of Hypoglycemia Increases as HbA1c Declines in Patients with Type 2 Diabetes 4 Annual Prevalence (%) Treatment with diet, sulfonylurea or metformin Most Recent HbA1c (%) Wright et al (26) J Diabetes Complications 2:395
3 Classification of Hypoglycemia (Clinical definition) Defined by individual s ability to self-treat or not MILD = self-treated SEVERE = external help required for recovery Severity is not determined by: symptom response conscious level nature of treatment
4 Pathophysiology of High Blood Glucose Excursions Blood coagulation Fibrinogen Prothrombin Factor VII Thrombocyte aggregation Polyol pathway PKC-activation Cell adhesion ICAM; VCAM E-selectin P-selectin Blood Glucose Spikes Inflammation hscrp IL-6 IL-18 TNF-α Endothelial dysfunction Oxidative stress Increased ADMA NO depletion Free fatty acids ADMA: Asymmetrical dimethyl arginine; hscrp: high sensitive C-reactive protein; ICAM: Intercellular adhesion molecule; IL: Interleukin; NO: Nitric oxide; PKC: Protein kinase C; TNF: Tumour necrosis factor; VCAM: Vascular cell adhesion molecule.
5 Pathophysiology of Low Blood Glucose Excursions Blood coagulation Fibrinogen Prothrombin Factor VII Platelet activation/aggregation White blood cells Mobilisation Activation Cell adhesion ICAM; VCAM E-selectin P-selectin Endothelial dysfunction vwf tpa VEGF Hypoglycaemia Inflammation hscrp IL-6 Endothelin-1 CD4 expression scd4l Free fatty acids hscrp: high sensitive C-reactive protein; ICAM: Intercellular adhesion molecule; IL: Interleukin; tpa: tissue plasminogen activator; scd4l: soluble CD4 Ligand; vwf: von Willebrand Factor; VCAM: Vascular cell adhesion molecule; VEGF: Vascular Endothelial Growth Factor.
6 Hypoglycemia as Pro-atherosclerotic factor
7 Frequency of Severe Hypoglycaemia in Types 1 and 2 Diabetes Annual prevalence of severe hypoglycaemia (%) (Severe: requiring external assistance) Type 2 DM Sulfonylureas (n = 13) Type 2 DM <2 years insulin (85) Type 2 DM >5 years insulin (75) Type 1 DM <5 years (46) Type 1 DM >15 years (54) T2DM SU T2DM < 2 yrs T2DM > 5 yrs T1DM < 5 yrs T1DM > 15 yrs Error bars = 95% confidence intervals Adapted from: UK Hypoglycaemia Study Group (27) Diabetologia 5:114.
8 Options for Antidiabetic Treatment Insulin Resistance Insulin Secretion Inhibition of Glucose Absorption Metformin Pioglitazone Canaglifozin Dapagliflozin Glucose independent Sulfonylurea Glinides Exogenous Insulin Glucose dependent DPP-4 Inhibitors (Alogliptin, Linagliptin, Saxagliptin, Sitagliptin, Vildagliptin) GLP-1 RA (Exenatide, Liraglutide, Lixisenatide) α-glucosidase Inhibitors (Acarbose,)
9 Combination Therapy with Non-insulin Antidiabetes Drugs: Hypoglycaemia Risk Meta-analysis analysis of Mixed Treatment Analysis of 24 trials Relative Risk of Hypoglycemia (95% Credible Interval) Phung et al, 21 JAMA 33: 141
10 Hypoglycaemia and Sulfonylureas Severe hypoglycaemia is more likely to occur within the first month of treatment (Asplund K et al. (1983) Diabetologia 24:412. Bodmer M et al. (28) Diabetes Care 31:286) Hypoglycaemia occurs more commonly when patients are treated with low doses (more sensitive to effect of drug) Hypoglycaemia is more common with long-acting preparations like glibenclamide Coma and serious morbidity occur secondary to sulfonylureainduced hypoglycaemia (Asplund K et al. (1983) Diabetologia 24:412. Asplund K et al. (1991) Diabet Med 8:726. Malouf & Brust, (1985) Ann Neurol 17: 421)
11 Hypoglycaemia Associated With Sulfonylureas Prevalence of Hypoglycaemia (%) % Glibenclamide % 14% 11% Chlorpropamide 2 Glibenclamide 3 Glimepiride 3 5% Gliclazide 4 2.9%* Glipizide 5 Sulfonylureas *Hypoglycaemia: capillary blood glucose <2.75 mmol/l ( 5 mg/dl) 1. Glucovance [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; UKPDS Group. Lancet 1998; 352: Draeger KE, et al. Horm Metab Res. 1996; 28: McGavin JK, et al. Drugs 22; 62; Metaglip [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 22
12 Age Distribution of Patients with Type 2 Diabetes with SU-induced Hypoglycaemia (n=139) Age in decades One third of cases were patients in nursing homes or being cared for by a home nursing service Holstein et al (21) Expert Opinion Drug Safety 9: 675
13 Impact of Type of previous Sulfonylurea Therapy on Mortality and CV Outcomes in Diabetic Patients with Acute Myocardial Infarction Gliclazide / Glimepiride (n=459) 18,3 22,5 Glibenclamide (n=263) 2,4 25, ,5 1,9 12,7 7,5 1,6 12,4 5 2,7 Death Arrhythmias, re-mi, stroke Any complication Patients on previous sulfonylurea therapy 2,4 Death Arrhythmias, re-mi, stroke Any complication Propensity score-matched cohorts Zeller et al. J Clin Endocrinol Metab 21; 95:
14 Effects of oral antidiabetic Drugs on HbA1c, Hypoglycemic Events & Weight Gain in 4 randomisied double blind large Studies (Quartet) Number HbA1c of Patients (%) Hypoglycemia (%) Weight Change (kg) Weight Difference (kg) 1 Metformin 1 Pioglitazone ,5-1,4 1, ,5 +1,9 4,4 2 SU 2 Pioglitazone 3 Metformin + Pioglitazone 3 Metformin + SU ,35-1,43-1,5-1, ,5 +1,4,9,1 4 SU + Pioglitazone 4 SU + Metformin ,35-1, ,8-1, 3,8 SU = Sulfonylureas 1 Schernthaner et al; JCEM 24; 89:668 3 Matthews et al; Diab.Metab Res.Rev.25; 21:167 2 Charbonell et al; Diabet Med. 25; 22:399 4 Hanefeld et al; Diab.Care 24;27:141
15 IDF Statement on Personalized Targets and Care in the Glycaemic Management of People with Type 2 Diabetes Properties of currently available blood glucose lowering agents AGIs Metformin SUs Glinides TZDs DPP-Inhibitors GLP 1-agonists Insulin Effect on fasting glucose* Effect on post prandial glucose* Weight** Hypoglycemia risk Side effects Cost*** variable Global availability# Experience with the medication# *Effect: = neutral; + = mild; ++ = moderate; +++ = moderate to marked;++++ = marked **Effect:-= favourable; = neutral; + = mild gain; ++ = moderate gain; +++ = moderate to marked gain; ++++ = marked gain Risk: = neutral; + = mild; ++ = moderate; +++ = moderate to marked;++++ = marked ***Cost: + = cheap; ++ = quite cheap; +++ = expensive; ++++ = very expensive #Availability and experience:+ = very small; ++ = small; +++ = high; ++++ = very high There needs to be unequivocal cost-effectiveness advantages to justify the use of more expensive therapies, especially in poor countries
16 Changes of mean HbA1c by treatment and visit: Vildagliptin or Glimepiride add-on to Metformin Mean HbA1c (%) 7,5 7,25 7, 6,75 Vildagliptin 1 mg/day Glimepiride up to 6 mg/day 6,5 Vildagliptin 1 mg/day n = Glimepiride up to 6 mg/day n = Week Ferrannini et al. Diabetes, Obesity and Metabolism 29; 11:
17 Incidence and Severity of Hypoglycaemic Events with Vildagliptin or Glimepiride during the 52 week treatment period Number of patients with hypoglycaemia Number of hypoglycaemic events Number of severe hypoglycaemic events Vildagliptin 1 mg/day Glimepiride up to 6 mg/day Ferrannini et al. Diabetes, Obesity and Metabolism 29; 11:
18 Vildagliptin vs. gliclazide as add on to metformin Study purpose: to compare the effect of 52 weeks treatment with Vidagliptin 5 mg bid to gliclazide up to 32 mg daily as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy Target population: T2DM patients inadequately controlled on a stable metformin monotherapy (baseline HbA1c %) N** = 17 Metformin n=513 Vildagliptin 5 mg bid + Met n=494 Gliclazide up to 32 mg # + Met 4 weeks 52 weeks Filozof and Gautier. Diabetes Medicine. 21; 27:
19 Vildagliptin provides similar HbA1c reduction as gliclazide but with a better tolerability profile Mean HbA1c (%) Mean HbA1c Vilda 5 mg bid + Met Glic up to 32 mg + Met -.81% vilda + met -.84 glic +met Non-inferior Glic= gliclazide; Met= metformin; Vilda= vildagliptin; BL= baseline; EP= end point; * p<.1 Vilda vs Glic, 95% CI (-1.77, -.79), adjusted mean change from BL to EP; b) per protocol population; c) safety population; # All hypoglycemic events: grade 1 EP Time (Week) Mean difference of adjusted values:.4% 95%CI: -.11,.2 Incidence (%) Change Body weight b from BL to week 52 Adjusted Mean Change in body weight (kg) n/n= N= Patients with one or more hypos (%) 5 / 51 5 / 493 1, 1, * Number of events Number of hypoglycemic events# N= Mean BL ~ 85 kg Hypoglycemic events c Filozof and Gautier. Diabetes Medicine. 21; 27:
20 Addition of Sitagliptin to Rosiglitazone and Metformin Study: Incidence of Hypoglycemia at 54 Weeks All-Patients-as-Treated Population a Treatment Group N Patients With 1 Episode, n (%) Total Number of Episodes, n Sitagliptin 1 mg 17 7 (4.1) 1 Placebo 92 1 (1.1) 1 2 a Excluding data after initiation of glycemic rescue therapy. Data on file, MSD.
21 Significant relative weight loss and lower incidence of hypoglycemia with linagliptin compared to glimepiride Adjusted 1 means for body weight change from baseline ± SE Kg - FAS (OC) weeks Significant relative weight loss with linagliptin as compared to glimepiride (p-value <.1) Linagliptin Glimepiride Number of patients Number of patients with hypoglycemia (% of total) Patients with severe hypoglycemic episode 3 (% of patients with hypoglycemia) Incidence of hypoglycemia 2 Percent of patients - Treated set Glimepiride (36.1) 12 (4.3) 4.8x lower Linagliptin (7.5) 1 (1.7) Significantly lower incidence of hypoglycemia with linagliptin as compared to glimepiride (p-value <.1) 1 Model includes baseline HbA1c, baseline weight, number of prior OADs, treatment, week repeated within patients and week by treatment interaction 2 Hypoglycemic episode defined by a blood glucose 7 mg/dl 3 Event requiring assistance of another person to actively administer carbohydrate, glucagon or other resuscitative actions Source: Gallwitz et al. American Diabetes Association, 71th Scientific Sessions, San Diego, CA, June 24-28, 211; 39-LB
22 Cardiovascular events: Saxagliptin controlled Phase 2b/3 pooled population 5 Time to onset of first primary Major Adverse Cardiovascular Event (MACE) First adverse event (%) Control All saxagliptin Patients at risk Weeks Control 1, All saxagliptin 3,35 6 2,615 2,419 2,29 1, Saxagliptin, FDA s Endocrinologic and Metabolic Drugs Advisory Committee Briefing Document for April 29 Meeting: NDA Available at Accessed: 7 May, 9.
23 Objectives of developing IDeg Duration of action: Control fasting blood glucose with one injection in all individuals Flat time action profile: Lower risk of hypoglycaemia Day-to-day variability: Less hypoglycaemia and hyperglycaemia
24 Mean 26-hour Blood Glucose Level 7. Profiles at Steady-state.8U/kg.6U/kg.4U/kg 6.5 Glucose level (mmol/l) Time (hours) Nosek L et al. Diabetologia 211;54(suppl. 1):S429 (155-P); ADA 211;49-LB (NN )
25 Within-subject variability of IDeg and IGlar in T1DM Screening 2 21 days Follow-up 7 21 days IDeg OD (n=27) IGlar OD (n=27) days Inclusion criteria T1DM 12 months HbA 1c 1.% BMI kg/m 2 Age years 24-hour euglycaemic clamp Clinical trial.gov identifier: NCT Heise et al. Diabetes 211;6(Suppl. 1):A263 (Abstract 96-P)
26 Within-subject variability over time IDeg IGlar Heise et al. Diabetes 211;6(Suppl. 1):A263
27 Confirmed Hypoglycaemia Confirmed hypoglycaemia (cumulative events per 1 patients) SAS Comparisons: Estimates adjusted for multiple covariates Time (weeks) IDeg OD + IAsp (n=753) IGlar OD + IAsp (n=251) 18% lower rate p=.36 Hollander et al. IDF 211:P-1442; Diabetologia 211;54(suppl. 1):S421; Garber et al. Diabetes 211;6(suppl. 1):A23 (NN )
28 Hypoglycaemia: nocturnal episodes 2 IDeg OD (n=59) IGlar OD (n=59) % risk reduction RR:.42 p= Time (weeks) 16 Mean cumulative function Birkeland et al. Diabetes Care 211;34:661 5
29 There is increasing Evidence that Hypoglycemia has to be avoided in Risk Situations of Patients with Type 2 Diabetes Long duration of Diabetes/Macrovascular Complications Acute Myocardial Infraction/Stroke Akuter Impaired Renal Function (Chronic Kidney Disease) Myokardinfarkt/Schlaganfall Coronary Revascularisation Intensive Care Unit (CCU) Unawareness to Hypoglycemia High Age with Hypovigilance
30
Early treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
More informationNavigating the New Options for the Management of Type 2 Diabetes
Navigating the New Options for the Management of Type 2 Diabetes Clinical Associate Professor Mark Kennedy Department of General Practice, University of Melbourne Chair, Primary Care Diabetes Society of
More informationSupplementary Online Content
Supplementary Online Content Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of Noninsulin Antidiabetic Drugs Added to Therapy on Glycemic Control, Weight Gain, and Hypoglycemia in Type 2 Diabetes.
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationIDF Regions and global projections of the number of people with diabetes (20-79 years), 2013 and Diabetes Atlas -sixth Edition: IDF 2013
IDF Regions and global projections of the number of people with diabetes (20-79 years), 2013 and 2035 Diabetes Atlas -sixth Edition: IDF 2013 Diabetes Atlas -sixth Edition: IDF 2013 Chronic complications
More informationCOPYRIGHT. Treatment of Type 2 Diabetes: What To Do When Treatment with Metformin is Inadequate? Can We Achieve Therapeutic Goals More Safely?
Treatment of Type 2 Diabetes: What To Do When Treatment with Metformin is Inadequate? Can We Achieve Therapeutic Goals More Safely? Martin J. Abrahamson, MD FACP Associate Professor of Medicine, Harvard
More informationOral Agents. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
Oral Agents Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What would your ideal diabetes drug do? Effective in lowering HbA1c No hypoglycaemia No effect on weight/ weight
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationWhat s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital
What s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital Therapy considerations in T2DM Thiazoledinediones DPP IV inhibitors GLP 1 agonists Insulin Type Delivery Horizon scanning
More informationManagement of Type 2 Diabetes
Management of Type 2 Diabetes Pathophysiology Insulin resistance and relative insulin deficiency/ defective secretion Not immune mediated No evidence of β cell destruction Increased risk with age, obesity
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Dapagliflozin in combination therapy for the Final scope Remit/appraisal objective To appraise the clinical and
More informationIncretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors Timothy Bailey, MD, FACE, CPI Director, AMCR Institute,
More informationSulfoniluree e glinidi: pro e contro
Sulfoniluree e glinidi: pro e contro Giorgio Sesti Università Magna Graecia di Catanzaro ITALY T2DM anti-hyperglycaemic therapy: general recommendations Diabetes Care 35:1364-1379, 2012; Diabetologia 55:1577-1596,
More informationGLP-1RA and insulin: friends or foes?
Tresiba Expert Panel Meeting 28/06/2014 GLP-1RA and insulin: friends or foes? Matteo Monami Careggi Teaching Hospital. Florence. Italy Dr Monami has received consultancy and/or speaking fees from: Merck
More informationGlucose Control drug treatments
Glucose Control drug treatments It should be noted that glitazones are under suspicion of precipitating acute cardiac events and current recommendations contraindicate the use of glitazones in patients
More informationGLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
More informationLATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines?
LATE BREAKING STUDIES IN DM AND CAD Will this change the guidelines? Objectives 1. Discuss current guidelines for prevention of CHD in diabetes. 2. Discuss the FDA Guidance for Industry regarding evaluating
More informationA Practical Approach to the Use of Diabetes Medications
A Practical Approach to the Use of Diabetes Medications Juan Pablo Frias, M.D., FACE President, National Research Institute, Los Angles, CA Clinical Faculty, University of California, San Diego, CA OUTLINE
More informationDept of Diabetes Main Desk
Dept of Diabetes Main Desk 01202 448060 Glucose management in Type 2 Diabetes in Adults The natural history of type 2 diabetes is for HbA1c to deteriorate with time. A stepwise approach to treatment is
More informationType 2 Diabetes Mellitus hypoglycaemic agents
Type 2 Diabetes Mellitus hypoglycaemic agents Name Metformin Drug Name (eg brand name) Metformin (Diaformin Diabex) Cost / PBS per 28d mth $10.24 (1.5g dly) 1000mg+500mg / $4.44+$5.80 Concerns? Lactic
More informationMedical therapy advances London/Manchester RCP February/June 2016
Medical therapy advances London/Manchester RCP February/June 2016 Advances in medical therapies for diabetes mellitus Duality of interest: The speaker or institutions with which he is associated has received
More informationNational Horizon Scanning Centre. Saxagliptin (BMS ) for type 2 diabetes. April 2008
Saxagliptin (BMS 477118) for type 2 diabetes This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement
More informationEfficacy and Safety of Sitagliptin in Various Clinical Settings of T2DM
Efficacy and Safety of Sitagliptin in arious Clinical Settings of T2DM Young Min Cho, MD, PhD Division of Endocrinology and Metabolism Department of Internal Medicine Seoul National University College
More informationAlia Gilani Health Inequalities Pharmacist
Alia Gilani Health Inequalities Pharmacist THE SOUTH ASIAN HEALTH FOUNDATION (U.K.) (Registered Charity No. 1073178) 1. Case Study 2. Factors influencing prescribing 3. Special Considerations 4. Prescribing
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationDiabetic Management of the Cardiac Patient
Diabetic Management of the Cardiac Patient Dr Peter A Senior BMedSci MBBS PhD FRCP(E) Associate Professor, Director Division of Endocrinology, University of Alberta Disclosures Grants/Research Support:
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Canagliflozin in combination therapy for Final scope Remit/appraisal objective To appraise the clinical and cost effectiveness
More informationCurrent Diabetes Care for Internists:2011
Current Diabetes Care for Internists:2011 Petch Rawdaree, DM, MSc, DLSHTM Faculty of Medicine Vajira Hospital University of Bangkok Metropolis 19 th January 2011 ก ก 1. ก ก ก ก 2. ก ก ก ก ก 3. ก ก ก ก
More informationManagement of Type 2 Diabetes. Why Do We Bother to Achieve Good Control in DM2. Insulin Secretion. The Importance of BP and Glucose Control
Insulin Secretion Management of Type 2 Diabetes DG van Zyl Why Do We Bother to Achieve Good Control in DM2 % reduction 0-5 -10-15 -20-25 -30-35 -40 The Importance of BP and Glucose Control Effects of tight
More informationCAMBRIDGESHIRE JOINT PRESCRIBING GROUP DECISION DOCUMENT Recommendation made by CJPG to Commissioners and Prescribers
CAMBRIDGESHIRE JOINT PRESCRIBING GROUP DECISION DOCUMENT Recommendation made by CJPG to Commissioners and Prescribers Linagliptin (Trajenta, Boehringer Ingelheim Ltd) for the treatment of type 2 diabetes
More informationOverview T2DM medications. Winnie Ho
Overview T2DM medications Winnie Ho Diabetes in Australia 1.7 million Australians with diabetes, of these 85% have T2DM 2-fold excess risk CV death in patients with diabetes Risk factor for progression
More informationDiabetes update - Diagnosis and Treatment
Diabetes update - Diagnosis and Treatment Eugene J Barrett, MD,PhD Madge Jones Professor of Medicine Director, University of Virginia Diabetes Center Disclosures - None Case 1 - Screening for Diabetes
More informationNo Increased Cardiovascular Risk for Lixisenatide in ELIXA
ON ISSUES IN THE MANAGEMENT OF TYPE 2 DIABETES JUNE 2015 Coverage of data from ADA 2015, June 5 9 in Boston, Massachusetts No Increased Cardiovascular Risk for Lixisenatide in ELIXA First Cardiovascular
More informationDiabete: terapia nei pazienti a rischio cardiovascolare
Diabete: terapia nei pazienti a rischio cardiovascolare Giorgio Sesti Università Magna Graecia di Catanzaro Cardiovascular mortality in relation to diabetes mellitus and a prior MI: A Danish Population
More informationClinical Overview of Combination Therapy with Sitagliptin and Metformin
Clinical Overview of Combination Therapy with Sitagliptin and Metformin 1 Contents Pathophysiology of type 2 diabetes and mechanism of action of sitagliptin Clinical data overview of sitagliptin: Monotherapy
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationDipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol
Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationSIMPLICITY IN T2DM MANAGEMENT WITH DPP4 INHIBITORS: SPECIAL POPULATION
SIMPLICITY IN T2DM MANAGEMENT WITH DPP4 INHIBITORS: SPECIAL POPULATION DR ROSE ZHAO-WEI TING ( 丁昭慧醫生 ) MBBS (HK), MRCP (UK), FHKCP, FHKAM (MEDICINE) Specialist in Endocrinology, Diabetes and Metabolism
More informationYOU HAVE DIABETES. Angie O Connor Community Diabetes Nurse Specialist 25th September 2013
YOU HAVE DIABETES Angie O Connor Community Diabetes Nurse Specialist 25th September 2013 Predicated 2015 figures are already met 1 in 20 have diabetes:1in8 over 60years old Definite Diagnosis is key Early
More informationOld oral antidiabetic agents in the armamentarium of diabetes mellitus treatment: Safety and efficacy
Old oral antidiabetic agents in the armamentarium of diabetes mellitus treatment: Safety and efficacy Melpomeni Peppa Assistant Professor of Endocrinology 2 nd Dept of Internal Medicine-Propaedeutic, Athens
More informationGLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
GLP-1 agonists Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What do GLP-1 agonists do? Physiology of postprandial glucose regulation Meal ❶ ❷ Insulin Rising plasma
More informationFixed dose combination for Trusted Diabetes Control Lobna Farag Eltooy Head of Internal Medicine Department Assiut University
Fixed dose combination for Trusted Diabetes Control By Lobna Farag Eltooy Head of Internal Medicine Department 1 Assiut University 3/18/2018 3/18/2018 3/18/2018 Diabetes Complications with Increasing HbA1c
More informationMetabolic Karma. - Essential Solution in Type2 DM - Eun Gyoung Hong, M.D., Ph.D
2014 ICDM Breakfast Symposium. Oct 18, 2014 Grand Hilton, Seoul Metabolic Karma - Essential Solution in Type2 DM - Eun Gyoung Hong, M.D., Ph.D Department of Endocrinology and Metabolism, Hallym University
More informationNewer Drugs in the Management of Type 2 Diabetes Mellitus
Newer Drugs in the Management of Type 2 Diabetes Mellitus Dr. C. Dinesh M. Naidu Professor of Pharmacology, Kamineni Institute of Medical Sciences, Narketpally. 1 Presentation Outline Introduction Pathogenesis
More informationCurrent principles of diabetes management
Current principles of diabetes management Prof. Martin Haluzík, MD, DSc. 3 Department of Medicine, General University Hospital and 1st Faculty of Medicine, Charles University in Prague, Czech Republic
More informationSitagliptin: A component of incretin based therapy. Rezvan Salehidoost, M.D., Endocrinologist
Sitagliptin: A component of incretin based therapy Rezvan Salehidoost, M.D., Endocrinologist Agenda Mode of Action Evidences for sitagliptine cardiovascular safety of sitagliptin Ramadan study Impact of
More informationHanyang University Guri Hospital Chang Beom Lee
Hanyang University Guri Hospital Chang Beom Lee Meal prayer, Van Brekelenkam 17 th C Introduction 2012 ADA/EASD Position Statement Proper Patients for Pioglitazone β-cell Preservation by Pioglitazone Benefit
More informationdapagliflozin 5mg and 10mg film-coated tablets (Forxiga ) SMC No. (799/12) Bristol-Myers Squibb / AstraZeneca
dapagliflozin 5mg and 10mg film-coated tablets (Forxiga ) SMC No. (799/12) Bristol-Myers Squibb / AstraZeneca 07 September 2012 (Issued 07 December 2012) The Scottish Medicines Consortium (SMC) has completed
More informationRole of incretins in the treatment of type 2 diabetes
Role of incretins in the treatment of type 2 diabetes Jens Juul Holst Department of Medical Physiology Panum Institute University of Copenhagen Denmark Diabetes & Obesity Spanish Society of Internal Medicine
More informationCONTROLLO GLICEMICO NEL PAZIENTE CON DMT2: E' SUFFICIENTE HbA1C? Contrario. Antonio Ceriello a,b
CONTROLLO GLICEMICO NEL PAZIENTE CON DMT2: E' SUFFICIENTE HbA1C? Contrario Antonio Ceriello a,b Excessive Glucose Fluctuations With Same A1C Values 400 Mean A1C = 6.7% Glucose Concentration (mg/dl) 300
More informationCardiovascular Management of a Patient with Diabetes
Cardiovascular Management of a Patient with Diabetes Dr Jeremy Krebs Clinical Leader Endocrinology and Diabetes Wellington Hospital Summary People with diabetes take a lot of medication Compliance and
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationIntensifying Treatment Beyond Monotherapy in T2DM: Where Do Newer Therapies Fit?
Intensifying Treatment Beyond Monotherapy in T2DM: Where Do Newer Therapies Fit? Vanita R. Aroda, MD Scientific Director & Physician Investigator MedStar Community Clinical Research Center MedStar Health
More informationClinical Relevance of Blood Pressure Lowering Effect of Modern Antidiabetic Drugs
Clinical Relevance of Blood Pressure Lowering Effect of Modern Antidiabetic Drugs Professor Guntram Schernthaner Medical University of Vienna, Austria guntram.schernthaner@meduniwien.ac.at Agenda Glucose
More informationMultiple Small Feedings of the Mind: Diabetes. Sonja K Fredrickson, MD, BC-ADM March 7, 2014
Multiple Small Feedings of the Mind: Diabetes Sonja K Fredrickson, MD, BC-ADM March 7, 2014 Question 1: Setting A1c Goals Describe the evidence based approach to determining the target HgbA1c in different
More informationPre-diabetes. Pharmacological Approaches to Delay Progression to Diabetes
Pre-diabetes Pharmacological Approaches to Delay Progression to Diabetes Overview Definition of Pre-diabetes Risk Factors for Pre-diabetes Clinical practice guidelines for diabetes Management, including
More informationCOMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date)
Drug, Treatment, Device name ( Vipidia; Takeda) COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date) Licensed indication To improve glycaemic control in
More informationUpdate on Insulin-based Agents for T2D. Harry Jiménez MD, FACE
Update on Insulin-based Agents for T2D Harry Jiménez MD, FACE Harry Jiménez MD, FACE Has received honorarium as Speaker and/or Consultant for the following pharmaceutical companies: Eli Lilly Merck Boehringer
More informationGlucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol
Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationGlucose Control and Prevention of Cardiovascular Disease
Glucose Control and Prevention of Cardiovascular Disease Dr Peter A Senior BMedSci MBBS PhD FRCP(E) Associate Professor, Director Division of Endocrinology, University of Alberta Diabetes Update+, March
More informationAge-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes
Age-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes Obesity (BMI 30 kg/m 2 ) 1994 2000 2009 No Data 26.0% Diabetes 1994 2000 2009
More informationTreatment Options for Diabetes: An Update
Treatment Options for Diabetes: An Update A/Prof. Marg McGill Manager, Diabetes Centre Dr. Ted Wu Staff Specialist Endocrinologist Diabetes Centre Centre of Health Professional Education Education Provider
More informationUpdate on Cardiovascular Outcome Trials in Diabetes. Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013
Update on Cardiovascular Outcome Trials in Diabetes Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013 Residual Vascular Risk in People with Diabetes 2 Analyses based on 530,083 participants
More informationempagliflozin 10mg and 25mg tablet (Jardiance ) SMC No. (993/14) Boehringer Ingelheim / Eli Lilly
empagliflozin 10mg and 25mg tablet (Jardiance ) SMC No. (993/14) Boehringer Ingelheim / Eli Lilly 05 September 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationMulti-factor approach to reduce cardiovascular risk in diabetes
Multi-factor approach to reduce cardiovascular risk in diabetes Prof. Nicola Napoli, MD PhD Division of Endocrinology and Diabetes Università Campus Bio-Medico di Roma Washington University in St Louis
More informationTREATMENTS FOR TYPE 2 DIABETES. Susan Henry Diabetes Specialist Nurse
TREATMENTS FOR TYPE 2 DIABETES Susan Henry Diabetes Specialist Nurse How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management
More informationProfessor Rudy Bilous James Cook University Hospital
Professor Rudy Bilous James Cook University Hospital Rate per 100 patient years Rate per 100 patient years 16 Risk of retinopathy progression 16 Risk of developing microalbuminuria 12 12 8 8 4 0 0 5 6
More informationESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A
More informationCan We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists
Can We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists Robert R. Henry, MD Professor of Medicine University of California, San Diego Relevant Conflict
More informationDiabetes Mellitus: Implications of New Clinical Trials and New Medications
Diabetes Mellitus: Implications of New Clinical Trials and New Medications Estimates of Diagnosed Diabetes in Adults, 2005 Alka M. Kanaya, MD Asst. Professor of Medicine UCSF, Primary Care CME October
More informationBasal & GLP-1 Fixed Combination Use
Basal & GLP-1 Fixed Combination Use Michelle M. Mangual, MD Diplomate of the American board of Internal Medicine and Endocrinology, Diabetes and Metabolism San Juan City hospital Learning Objectives o
More informationMANAGEMENT OF TYPE 2 DIABETES
MANAGEMENT OF TYPE 2 DIABETES 3 Month trial of lifestyle changes. Refer to DESMOND structured education programme. Set glycaemic target HbA1c < 7.0% (53mmol/mol) or individualised If HbA1c > 53mmol/mol
More informationHot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care
Hot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care Mary Jean Christian, MA, MBA, RD, CDE Diabetes Program Coordinator UC Irvine Health Hot Topics: Diabetes
More informationJoslin Diabetes Center Joslin Diabetes Forum 2013: The Impact of Comorbidities on Glucose Control Scenario 2: Reduced Renal Function
Scenario 2: Reduced Renal Function 62 y.o. white man with type 2 diabetes for 18 years Hypertension and hypercholesterolemia Known proliferative retinopathy Current medications: Metformin 1000 mg bid Glyburide
More informationsitagliptin, 25mg, 50mg and 100mg film-coated tablets (Januvia ) SMC No. (1083/15) Merck Sharp and Dohme UK Ltd
sitagliptin, 25mg, 50mg and 100mg film-coated tablets (Januvia ) SMC No. (1083/15) Merck Sharp and Dohme UK Ltd 07 August 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationInsulin Initiation and Intensification. Disclosure. Objectives
Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School
More informationShould Psychiatrists be diagnosing (and treating) metabolic syndrome
Should Psychiatrists be diagnosing (and treating) metabolic syndrome David Hopkins Clinical Director, Diabetes King s College Hospital, London Diabetes prevalence (thousands) Diabetes in the UK: 1995-2010
More informationModulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes
Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Adjunct Professor at University of Appalachia College of Pharmacy Clinical Associate, Medical
More informationDr. Stanley Ho Medical Development Foundation Symposium Jan 2014 Advances in the Management of Type 2 Diabetes Mellitus
Dr. Stanley Ho Medical Development Foundation Symposium 2014 18 Jan 2014 Advances in the Management of Type 2 Diabetes Mellitus Dr Ronald Ma Professor Dept of Medicine & Therapeutics Prince of Wales Hospital
More informationSIGN 154 Pharmacological management of glycaemic control in people with type 2 diabetes. A national clinical guideline November 2017.
SIGN 154 Pharmacological management of glycaemic control in people with type 2 diabetes A national clinical guideline November 2017 Evidence KEY TO EVIDENCE STATEMENTS AND RECOMMENDATIONS LEVELS OF EVIDENCE
More informationFrancesca Porcellati
XX Congresso Nazionale AMD Razionali e Benefici dell Aggiunta del GLP-1 RA Short-Acting all Insulina Basale Francesca Porcellati Dipartimento di Medicina Interna, Sezione di Medicina Interna, Endocrinologia
More informationMetformin. Sulfonylurea. Thiazolidinedione. Insulin
동아의대내분비내과박미경 Metformin Sulfonylurea Thiazolidinedione Insulin 요약 markers of inflammation (hs-crp, TNF-a) markers of impaired endothelial function (VFW, scams, tpa, PAI-1) LDL-C, fasting and postprandial
More informationAchieving and maintaining good glycemic control is an
Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE; Kathleen Wyne, MD, PhD, FACE, FNLA; Anthony Cannon,
More informationThe promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease
The promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease Steve Smith, Group Director Scientific Affairs, Diabetes & Metabolism GlaxoSmithKline R & D
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 2 December 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 2 December 2009 VICTOZA 6 mg/ml solution for injection in pre-filled pen Pack size of two 3 ml pens (CIP: 396 323-6)
More informationPhysiology of Normoglycemia
Case 1 45 year-old male patient seen at the clinic (Medicine). Workplace stress (financial analyst); occasionally goes jogging. Two-year duration of T2DM. No previous cardiovascular events. Coexisting
More informationLiraglutide (Victoza) in combination with basal insulin for type 2 diabetes
Liraglutide (Victoza) in combination with basal insulin for type 2 diabetes May 2011 This technology summary is based on information available at the time of research and a limited literature search. It
More informationDrug Class Monograph
Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Monograph Drugs: alogliptin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin), Jentadueto (linagliptin/metformin),
More informationDisclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare
Disclosure Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Spring Therapeutics Update 2011 CSHP BC Branch Anar Dossa BScPharm Pharm D CDE April 20, 2011
More informationVery Practical Tips for Managing Type 2 Diabetes
Very Practical Tips for Managing Type 2 Diabetes Jean-François Yale, MD, FRCPC McGill University Health Centre, Montreal, Canada Jean-francois.yale@mcgill.ca www.dryale.ca OBJECTIVES DISCLOSURES The participant
More informationHorizon Scanning Technology Summary. Liraglutide for type 2 diabetes. National Horizon Scanning Centre. April 2007
Horizon Scanning Technology Summary National Horizon Scanning Centre Liraglutide for type 2 diabetes April 2007 This technology summary is based on information available at the time of research and a limited
More informationUpdate on Diabetes Cardiovascular Outcome Trials
Update on Diabetes Cardiovascular Outcome Trials Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationSCIENTIFIC STUDY REPORT
PAGE 1 18-NOV-2016 SCIENTIFIC STUDY REPORT Study Title: Real-Life Effectiveness and Care Patterns of Diabetes Management The RECAP-DM Study 1 EXECUTIVE SUMMARY Introduction: Despite the well-established
More informationHow can we improve outcomes in Type 2 diabetes?
How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management Identify and treat all risk factors Use rational pharmacological therapy
More informationGalvus the most comprehensively studied DPP-4 inhibitor
Galvus the most comprehensively studied DPP-4 inhibitor! >7 000 patients enrolled in clinical studies! >4 00 patients exposed to Galvus >1 300 patients exposed 2 weeks >300 patients exposed for 104 weeks!
More informationUKPDS: Over Time, Need for Exogenous Insulin Increases
UKPDS: Over Time, Need for Exogenous Insulin Increases Patients Requiring Additional Insulin (%) 60 40 20 Oral agents By 6 Chlorpropamide years, Glyburide more than 50% of UKPDS patients required insulin
More informationAgenda. Indications Different insulin preparations Insulin initiation Insulin intensification
Insulin Therapy F. Hosseinpanah Obesity Research Center Research Institute for Endocrine sciences Shahid Beheshti University of Medical Sciences November 11, 2017 Agenda Indications Different insulin preparations
More informationDrug Class Monograph
Drug Class Monograph Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drugs: alogliptin, alogliptin/metformin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin),
More informationScottish Medicines Consortium
Scottish Medicines Consortium liraglutide 6mg/mL prefilled pen for injection (3mL) (Victoza ) Novo Nordisk Ltd. No. (585/09) 06 November 2009 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationLe incretine: un passo avanti. Francesco Dotta
Le incretine: un passo avanti Francesco Dotta U.O.C. Diabetologia, Policlinico Le Scotte Università di Siena Fondazione Umberto Di Mario ONLUS Toscana Life Science Park Incretins: multiple targets multiple
More information